Episode 64
Biotech Hangout
00:00
Intercept for Nash Fibrosis: A Dynamic Plan
I know that there's a lot of uncertainty about the label and the narrow restriction, uh, around the ages. Mike, do you want to comment on this? And then also, um, we can talk about the, um, URL that intercept got for its Nash fibrosis drug. Uh, yeah, I don't have much more to add to what he just said. Although obviously there's a major randomized controlled study coming in a few months which should answer a lot of questions here.
Transcript
Play full episode
